Ginkgo Bioworks Holdings, Inc. $DNA Shares Bought by UBS Group AG

UBS Group AG grew its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 86.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 489,418 shares of the company’s stock after acquiring an additional 226,861 shares during the period. UBS Group AG owned about 0.81% of Ginkgo Bioworks worth $4,067,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in Ginkgo Bioworks during the 2nd quarter worth $29,000. Quarry LP acquired a new position in shares of Ginkgo Bioworks in the 3rd quarter valued at about $29,000. Strs Ohio bought a new stake in shares of Ginkgo Bioworks during the 3rd quarter valued at about $44,000. Daiwa Securities Group Inc. bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter valued at about $71,000. Finally, State of Wyoming acquired a new stake in Ginkgo Bioworks during the third quarter worth about $74,000. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Stock Up 4.2%

Shares of DNA stock opened at $8.42 on Friday. The business has a 50 day moving average of $7.51 and a two-hundred day moving average of $8.41. The company has a market cap of $549.80 million, a P/E ratio of -1.57 and a beta of 1.77. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.37 and a 52 week high of $17.58.

Ginkgo Bioworks (NYSE:DNA) last posted its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. The firm had revenue of $33.40 million during the quarter, compared to analyst estimates of $37.57 million. Ginkgo Bioworks had a negative net margin of 215.41% and a negative return on equity of 56.08%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DNA. BTIG Research cut their target price on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks currently has an average rating of “Reduce” and an average price target of $8.50.

Insider Activity

In other Ginkgo Bioworks news, insider Steven P. Coen sold 33,171 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $6.41, for a total transaction of $212,626.11. Following the completion of the transaction, the insider directly owned 49,849 shares of the company’s stock, valued at $319,532.09. The trade was a 39.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Barry Canton sold 124,727 shares of the business’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $6.43, for a total transaction of $801,994.61. Following the transaction, the insider directly owned 436,422 shares of the company’s stock, valued at $2,806,193.46. The trade was a 22.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 542,981 shares of company stock valued at $3,548,999. Company insiders own 12.69% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.